An analysis of patient-reported outcomes in ixora-s : Comparing ixekizumab and ustekinumab over 52 weeks in moderate-to-severe psoriasis
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Lomaga, Mark (DermEdge Research and Probity Medical Research)
Hollister, Kristin (Eli Lilly and Company)
Dutronc, Yves (Eli Lilly and Company)
Berggren, Lovisa (HaaPACS GmbH)
Van De Kerkhof, Peter C.M. (Radboud University Nijmegen Medical Centre)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	Patient-reported outcomes are valuable for assessing new psoriasis therapies. This study investigated patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with ixekizumab or ustekinumab, dosed according to their respective labels, for 52 weeks (IXORA-S-NCT02561806). Patient-reported outcomes investigated included patient global assessment, pruritus, skin pain, health-related quality of life, and work productivity. Ixekizumab-treated patients reported greater improvements in patient-reported outcomes sooner after treatment compared with ustekinumab-treated patients, and maintained greater improvements in patient global assessment scores (ixekizumab 0. 72, ustekinumab 1. 19; p < 0. 001), rates of Dermatology Life Quality Index (0, 1) (ixekizumab 71. 3%, ustekinumab 56. 6%, p < 0. 01), and 36-item Short-form Health survey physical component summary score change from baseline (ixekizumab 5. 53, ustekinumab 3. 28; p <0. 05) at week 52. While clinically meaningful improvements in patient-reported outcomes resulted with either treatment, ixekizumab provided more rapid improvements in patient-reported outcomes and superior outcomes for some assess-ments through one year of treatment, while maintaining statistically superior improvements in skin severity, as assessed by either physicians or patients.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Health-related quality of life ; Ixekizumab ; Patient-reported outcomes ; Ustekinumab
Publicat a:	Acta dermato-venereologica, Vol. 100 Núm. 19 (2020) , p. 1-7, ISSN 1651-2057

DOI: 10.2340/00015555-3700
PMID: 33236124

7 p, 769.8 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats